标题
Role of Janus Kinase Inhibitors in Therapy of Psoriasis
作者
关键词
-
出版物
Journal of Clinical Medicine
Volume 10, Issue 19, Pages 4307
出版商
MDPI AG
发表日期
2021-09-23
DOI
10.3390/jcm10194307
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020 – a rapid update
- (2020) C.H. Smith et al. BRITISH JOURNAL OF DERMATOLOGY
- A novel treatment for psoriatic arthritis
- (2020) Miao Chen et al. CHINESE MEDICAL JOURNAL
- Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015-2018)
- (2019) Xingrui He et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases
- (2019) Anniina T. Virtanen et al. BIODRUGS
- A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis
- (2019) Katie Bechman et al. RHEUMATOLOGY
- Population pharmacokinetics of tofacitinib in patients with psoriatic arthritis
- (2019) Rujia Xie et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Remission Duration and Long-Term Outcomes in Patients with Moderate-to-Severe Psoriasis Treated by Biologics or Tofacitinib in Controlled Clinical Trials: A 15-Year Single-Center Experience
- (2019) Yi-Wei Huang et al. Dermatology and Therapy
- The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors
- (2019) Katie Bechman et al. PHARMACOLOGICAL RESEARCH
- Mini Review: New Treatments in Psoriatic Arthritis. Focus on the IL-23/17 Axis
- (2019) Lazaros I. Sakkas et al. Frontiers in Pharmacology
- Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases
- (2019) Kata P. Szilveszter et al. Frontiers in Immunology
- The JAK inhibitor tofacitinib ameliorates immune‑mediated liver injury in mice
- (2019) Han Wang et al. Molecular Medicine Reports
- Targeting the Janus Kinase Family in Autoimmune Skin Diseases
- (2019) Michael D. Howell et al. Frontiers in Immunology
- Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib
- (2019) Elena Maria Elli et al. Frontiers in Oncology
- Emerging Topical and Systemic JAK Inhibitors in Dermatology
- (2019) Farzan Solimani et al. Frontiers in Immunology
- Systemic Treatment of Psoriasis with JAK Inhibitors: A Review
- (2019) Amanda Kvist-Hansen et al. Dermatology and Therapy
- Herpes Zoster in Patients Receiving JAK Inhibitors For Ulcerative Colitis: Mechanism, Epidemiology, Management, and Prevention
- (2018) Jean-Frédéric Colombel INFLAMMATORY BOWEL DISEASES
- Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis
- (2018) Uma Mahadevan et al. INFLAMMATORY BOWEL DISEASES
- Reduction of Inflammatory and Cardiovascular Proteins in the Blood of Patients with Psoriasis: Differential Responses between Tofacitinib and Etanercept after 4 Weeks of Treatment
- (2018) Jaehwan Kim et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- OUP accepted manuscript
- (2018) RHEUMATOLOGY
- OUP accepted manuscript
- (2018) RHEUMATOLOGY
- Genomic alterations driving psoriasis pathogenesis
- (2018) S. Singh et al. GENE
- Systemic Tofacitinib Concentrations in Adult Patients With Atopic Dermatitis Treated With 2% Tofacitinib Ointment and Application to Pediatric Study Planning
- (2018) Vivek S. Purohit et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial
- (2018) Philip Mease et al. LANCET
- Comparative risk of venous thromboembolism with tofacitinib versus tumor necrosis factor inhibitors: A cohort study of rheumatoid arthritis patients
- (2018) Rishi J. Desai et al. Arthritis & Rheumatology
- Tofacitinib Is the Right OCTAVE for Ulcerative Colitis
- (2017) Lieven Pouillon et al. GASTROENTEROLOGY
- Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis
- (2017) Robert Wolk et al. Journal of Clinical Lipidology
- The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients
- (2017) Michael Abrouk et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Herpes zoster in psoriasis patients treated with tofacitinib
- (2017) Kevin L. Winthrop et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata
- (2017) Cheryl B. Bayart et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
- (2017) Daniella M. Schwartz et al. NATURE REVIEWS DRUG DISCOVERY
- Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis
- (2017) Philip Mease et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors
- (2017) Dafna Gladman et al. NEW ENGLAND JOURNAL OF MEDICINE
- A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis
- (2016) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis
- (2016) Robert Bissonnette et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Disease Activity and Increased Risk of Cardiovascular Death among Patients with Psoriatic Arthritis
- (2016) K. Juneblad et al. JOURNAL OF RHEUMATOLOGY
- Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis
- (2016) Jashin J. Wu et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor
- (2016) Christina Charles-Schoeman et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist
- (2016) Christina Charles-Schoeman et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Incidence and predictors for cardiovascular events in patients with psoriatic arthritis
- (2015) Lihi Eder et al. ANNALS OF THE RHEUMATIC DISEASES
- A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis
- (2015) K. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Downmodulation of key inflammatory cell markers with a topical Janus kinase 1/2 inhibitor
- (2015) N. Punwani et al. BRITISH JOURNAL OF DERMATOLOGY
- Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial
- (2015) Hervé Bachelez et al. LANCET
- Specificity of JAK-kinase inhibition determines impact on human and murine T-cell function
- (2015) F Perner et al. LEUKEMIA
- Editorial: Decernotinib: A Next-Generation Jakinib
- (2015) Massimo Gadina et al. Arthritis & Rheumatology
- Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study
- (2014) Alexis Ogdie et al. ANNALS OF THE RHEUMATIC DISEASES
- The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis
- (2014) D L Boyle et al. ANNALS OF THE RHEUMATIC DISEASES
- Psoriasis
- (2014) P. Di Meglio et al. Cold Spring Harbor Perspectives in Medicine
- JAK Inhibitors: Treatment Efficacy and Safety Profile in Patients with Psoriasis
- (2014) Leeyen Hsu et al. Journal of Immunology Research
- Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment
- (2013) B. Strober et al. BRITISH JOURNAL OF DERMATOLOGY
- Quantifying cardiovascular disease risk factors in patients with psoriasis: a meta-analysis
- (2013) I.M. Miller et al. BRITISH JOURNAL OF DERMATOLOGY
- Pharmacokinetics of tofacitinib, a janus kinase inhibitor, in patients with impaired renal function and end-stage renal disease
- (2013) Sriram Krishnaswami et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Incidence of Cardiovascular Disease in Individuals with Psoriasis: A Systematic Review and Meta-Analysis
- (2013) Eleanor J. Samarasekera et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Higher Rates and Clustering of Abnormal Lipids, Obesity, and Diabetes Mellitus in Psoriatic Arthritis Compared With Rheumatoid Arthritis
- (2013) Monalyn Labitigan et al. ARTHRITIS CARE & RESEARCH
- Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis
- (2012) Naresh Punwani et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- JAK/STAT signaling in hematological malignancies
- (2012) W Vainchenker et al. ONCOGENE
- The many faces of Janus kinase
- (2011) Matthew M. Seavey et al. BIOCHEMICAL PHARMACOLOGY
- Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives
- (2010) G. D. Kitas et al. ANNALS OF THE RHEUMATIC DISEASES
- Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study
- (2010) O. Ahlehoff et al. JOURNAL OF INTERNAL MEDICINE
- Janus kinases in immune cell signaling
- (2009) Kamran Ghoreschi et al. IMMUNOLOGICAL REVIEWS
- JAK3: A two-faced player in hematological disorders
- (2009) Melanie G. Cornejo et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Cardiovascular morbidity in psoriatic arthritis
- (2008) D D Gladman et al. ANNALS OF THE RHEUMATIC DISEASES
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started